Initial In Vivo Evaluation of a Novel Left Ventricular Assist Device

Abstract EN

The aim of the study was to use the ovine model to evaluate the hemocompatibility and end-organ effects of a newly developed magnetic suspension centrifugal left ventricular assist device (LVAD) by CH Biomedical Inc., Jiangsu, China.

The LVADs were implanted in 6 healthy sheep, where inflow was inserted into the left ventricular apex and outflow was anastomosed to the descending aorta.

All sheep received anticoagulation and antiaggregation therapy during the study.

Hematologic and biochemical tests were performed to evaluate anemia, hepatorenal function, and the extent of hemolysis.

The experiments lasted for up to 30 days on the beating hearts.

All sheep were humanely killed at the termination of the experiments, and the end-organs were examined macroscopically and histopathologically.

Autopsy was performed in all animals and there was no thrombus formation observed inside the pump.

The pump’s inflow and outflow conduits were also free of thrombus.

Hematologic and biochemical test results were within normal limits during the study period.

Postmortem examination of the explanted organs revealed no evidence of ischemia or infarction.

Based on the in vivo study, this LVAD is suitable for implantation and can provide efficient support with good biocompatibility.

The encouraging results in this study suggest that it is feasible to evaluate the device’s long-term durability and stability.